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Summary
Background The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to 
rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert.
Methods We did a prospective, observational study of individuals who were enrolled in a Rwandan nationwide 
diagnostic cohort study (DIAMA trial; NCT03303963). We included patients identified to have rifampicin resistance 
on initial Xpert testing. We did a repeat Xpert assay and used rpoB Sanger and deep sequencing alongside phenotypic 
drug susceptibility testing (pDST) to ascertain final rifampicin susceptibility status, with any (hetero)resistant result 
overriding. We used multivariable logistic regression to assess predictors of false rifampicin resistance on initial 
Xpert testing, adjusted for HIV status, tuberculosis treatment history, initial Xpert semi-quantitative bacillary load, 
and initial Xpert probe.
Findings Between May 4, 2017, and April 30, 2019, 175 people were identified with rifampicin resistance at initial 
Xpert testing, of whom 154 (88%) underwent repeat Xpert assay. 54 (35%) patients were confirmed as rifampicin 
resistant on repeat testing and 100 (65%) were not confirmed with resistance. After further testing and sequencing, 
121 (79%) of 154 patients had a final confirmed status for rifampicin susceptibility. 57 (47%) of 121 patients were 
confirmed to have a false rifampicin resistance result and 64 (53%) had true rifampicin resistance. A high pretest 
probability of rifampicin resistance did not decrease the odds of false rifampicin resistance (adjusted odds ratio 
[aOR] 6·0, 95% CI 1·0–35·0, for new tuberculosis patients vs patients who needed retreatment). Ten (16%) of the 
64 patients with true rifampicin resistance did not have confirmed rifampicin resistance on repeat Xpert testing, of 
whom four had heteroresistance. Of 63 patients with a very low bacillary load on Xpert testing, 54 (86%) were falsely 
diagnosed with rifampicin-resistant tuberculosis. Having a very low bacillary load on Xpert testing was strongly 
associated with false rifampicin resistance at the initial Xpert assay (aOR 63·6, 95% CI 9·9–410·4). 
Interpretation The Xpert testing algorithm should include an assessment of bacillary load and retesting in case 
rifampicin resistance is detected on a paucibacillary sputum sample. Only when rifampicin resistance has been 
confirmed on repeat testing should multidrug-resistant tuberculosis treatment be started. When rifampicin resistance 
has not been confirmed on repeat testing, we propose that patients should be given first-line anti-tuberculosis drugs 
and monitored closely during treatment, including by baseline culture, pDST, and further Xpert testing. 
Funding The European & Developing Countries Clinical Trials Partnership 2 programme, and Belgian Directorate 
General for Development Cooperation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Timely detection of rifampicin-resistant tuberculosis as a 
proxy for multidrug-resistant (MDR) tuberculosis has been 
achieved widely through the roll-out of rapid molecular 
diagnostic methods, such as the Xpert MTB/RIF (Xpert) 
assay.1 These procedures allow swift initiation of appropriate 
MDR-tuberculosis treatment, which im proves outcomes 
and interrupts transmission of resistance.2,3
Detection of rifampicin resistance by the Xpert assay is 
based on absence or delay of binding of five probes 
(labelled A–E) that cover the 81 bp rifampicin-resistance 
determining region, as measured by a significant difference 
in the PCR threshold cycle (Ct) value (ie, the number of 
PCR cycles needed for initial detection of amplification) 
between the different probes (ΔCt>4). The Ct value gives a 
semi-quantitative measure of the tuberculosis bacillary 
load in the sample; for example, values can range from less 
than 16 (Ct<16, classified as high Mycobacterium tuberculosis 
complex detected) to greater than 28 (Ct>28, categorised as 
very low M tuberculosis complex detected).4
The Xpert assay was initially reported with an imperfect 
specificity that was actually attributable to missed 
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rifampicin resistance as detected by the gold-standard test 
(mostly, phenotypic drug-susceptibility testing [pDST]).5 
However, in a few case reports, false rifampicin resistance 
was also noted on Xpert testing.6,7 Findings of two studies 
identified false rifampicin resistance in small sets of 
paucibacillary sputum samples.4,8 In another report, false 
rifampicin resistance was associated with Xpert probe B 
and probe binding delay.9 Although the 2017 Global 
Laboratory Initiative (GLI) guideline recommends repeat 
Xpert testing in patients with a low pretest probability for 
rifampicin-resistant tuberculosis (eg, new patients who 
have not been in contact with a patient with rifampicin-
resistant tuberculosis),10,11 population-based data on the 
frequency of false rifampicin resistance on Xpert testing, 
and predictors for a false result, are not available.
The classic Xpert assay was introduced in six public 
hospitals in Rwanda in 2012, increasing to 68 centres in 
2019. Currently, Xpert testing is easily accessible as a first-
line tuberculosis diagnostic method for high-risk groups 
(eg, people aged ≥55 years, individuals with HIV co-
infection, children aged ≤15 years, contacts of tuberculosis 
patients, and prisoners). The assay is also used as a 
diagnostic method for rifampicin-resistant tuberculosis 
for all patients with a positive smear.12 Moreover, since 
2017, Xpert has been used as a first-line diagnostic 
method for all patients with presumptive tuberculosis in 
Kigali, where more than 55% of patients with notified 
rifampicin-resistant tuberculosis in Rwanda reside.
The DIAgnostics for Multidrug resistant tuberculosis in 
Africa (DIAMA) trial is an ongoing trial of molecular 
diagnostic tests for MDR-tuberculosis in Rwanda 
(NCT03303963). During this trial, frequent discordance 
was seen between initial and repeat Xpert test results. 
Thus, we decided post hoc to do a population-wide, pros-
pec tive observational study to investigate factors associated 
with false rifampicin resistance on Xpert testing.
Methods
Design and study population
We did a population-wide, prospective observational study 
at peripheral health facilities in Rwanda. We included in 
our analysis all people enrolled in the DIAMA trial who 
were diagnosed with rifampicin-resistant tuberculosis on 
initial Xpert testing. We excluded patients enrolled in the 
DIAMA trial who initiated MDR-tuber culosis treatment 
on the basis of clinical decision; who had a line probe 
assay resistance diagnosis; who had a GenoType 
MTBDRplus (Hain Lifescience, Nehren, Germany) 
resistance diagnosis; who were judged to have extra-
pulmonary rifampicin-resistant tuberculosis; or for whom 
an initial Xpert test result was not available. 
The DIAMA study protocol was approved by the 
Rwandan national ethics committee (Institutional 
Review Board 00001497 of IORG0001100; ref no 0069/
RNEC/2017). All participants provided informed consent 
or assent.
Procedures
For the initial Xpert assay (Cepheid, Sunnyvale, CA, 
USA), all individuals received a prelabelled container and 
Research in context
Evidence before this study
We searched PubMed for all studies published before 
February, 2020, in which false rifampicin resistance results on 
Xpert MTB/RIF (Xpert) testing were reported, using 
combinations of keywords: (“false” OR “discordance” OR 
“discordant”), AND (“rifampicin-resistant” OR “rifampicin 
resistance”), AND (“Xpert MTB/RIF” OR “GeneXpert”). Only a 
few studies, mainly case reports or case series, reported false 
rifampicin resistance on Xpert testing, particularly in samples 
with a very low bacillary load. Findings of previous studies 
suggested an association between false rifampicin resistance 
and probe B or delayed binding of probes, but no estimates 
have been made of the frequency and predictors of false 
rifampicin resistance results on Xpert testing in the setting of a 
national tuberculosis programme.
Added value of this study
Our analysis includes patients enrolled into a nationwide cohort 
study. Our findings show at the population level that false 
rifampicin resistance on Xpert can be very frequent. In our setting 
of low prevalence of rifampicin resistance, close to half (47%) of 
rifampicin resistance diagnosed on Xpert was false. Our study 
confirmed previous findings that false rifampicin resistance 
results on Xpert testing are driven by a very low bacillary load in 
the sample. Moreover, a high pretest probability of rifampicin 
resistance (ie, in patients with previous tuberculosis) did not 
decrease the odds of false rifampicin resistance results on Xpert 
testing. Further, repeat Xpert testing might not rule out true 
rifampicin resistance, particularly in individuals with 
heteroresistance.
Implications of all the available evidence
The findings of this study warrant a modification of the 
recommended Xpert testing flowchart, in which patients who 
test rifampicin resistant on the initial Xpert assay currently 
receive treatment for multidrug-resistant (MDR) disease, 
regardless of having true or false rifampicin resistance. 
In addition to a low pretest probability as an indication to 
repeat the Xpert assay, repeat testing on a better sample 
(ie, obtained after clearly instructing patients or using an 
early-morning sample) should be done for samples with 
rifampicin-resistant results but a very low bacillary load. 
Moreover, if rifampicin-resistant tuberculosis is not confirmed 
at repeat Xpert testing, further testing during MDR-tuberculosis 
treatment and follow-up should be considered to overcome 
false rifampicin susceptibility because of heteroresistance. 
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were instructed at their respective peripheral health faci-
lity how to provide a sputum sample. The specimen was 
stored at 2–8°C before shipment in a cool box (at 
approximately 4°C) to one of 68 peripheral Xpert testing 
laboratories in Rwanda. Samples were tested within 
2 days after the initial collection date under a quality 
assurance programme (Xpert testing sites had imple-
men ted a continuous quality improvement scheme 
and successfully partic ipated in annual US Centers for 
Disease Control and Prevention proficiency panel testing 
since 2018).
Per routine in Rwanda, all patients identified with 
rifampicin-resistant tuberculosis on the initial Xpert 
assay were referred to one of two MDR-tuberculosis 
clinics (located in Kigali and Huye). Before starting 
treatment for MDR-tuberculosis, three additional 
sputum samples were obtained, the first on the day of 
arrival (spot sample 1), the second overnight (sample 2; 
ie, sputum continuously produced in the same container 
during the night), and the third the next day (spot 
sample 3). All three samples and a data sheet were sent 
to the National Reference Laboratory (NRL) in Kigali on 
the same day the third sample was obtained in a cool box 
(at approximately 4°C). All patients started a short MDR-
tuberculosis treatment regimen (9 months’ duration) 
and were treated regardless of subsequent test results.
The repeat Xpert test was done at the NRL within 
2 days of sample collection; the overnight sample was 
used for testing because sample 2 typically had a higher 
volume than did spot samples 1 and 3, allowing different 
assays to be done on the same sample. Sample 3 and the 
remainder of sample 2 were processed separately for 
mycobacterial culture at the NRL.13 Sample 1 was stored 
for future testing. Positive cultures were confirmed for 
presence of acid-fast bacilli by Ziehl-Neelsen microscopy. 
Identification of M tuberculosis complex was confirmed 
using an immunochromatographic test (SD MPT64TB 
Ag kit; SD Bioline, Seoul, South Korea). Positive cultures 
underwent pDST for rifampicin and other anti-
tuberculosis drugs (including isoniazid, ethambutol, 
Figure 1: Rifampicin susceptibility testing flowchart
Repeat Xpert testing was done on an overnight sample obtained at specialised MDR-TB treatment clinics. GenoType MTBDRplus is an MDR-TB diagnostic test. 
Xpert=classic Xpert MTB/RIF assay. MDR-TB=multidrug-resistant tuberculosis. RR=rifampicin resistant. RS=rifampicin susceptible. RI=rifampicin indeterminate.
3 true RR 6 true RR
1 true RR54 true RR
      4 very low bacillary load on 
          initial Xpert testing 
54 reference method available 38 reference method available 28 reference method available 1 reference method available
46 RS on repeat Xpert testing 53 tuberculosis-negative on 
      repeat Xpert testing
100 not confirmed as RR on repeat 
         Xpert testing
54 confirmed as RR on repeat Xpert 
       testing
1 RI on repeat Xpert testing
35 false RR
      33 very low bacillary load on 
            initial Xpert testing   
22 false RR
      21 very low bacillary load on 
            initial Xpert testing
193 started on MDR-TB treatment in Rwanda
175 RR on initial Xpert testing and enrolled in
         this study
154 considered for analysis
18 excluded (not eligible for analysis)
      11 based on GenoType MTBDRplus
        4 based on clinical decision
         3 extrapulmonary RR-tuberculosis
21 excluded (initial Xpert semi-quantitative 
 bacillary load not available) 
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streptomycin, kanamycin, capreomycin, and ofloxacin) 
using the proportion method on Löwenstein-Jensen 
medium, with the final reading at 4 weeks for ethambutol 
and 6 weeks for the other drugs.14
If participants were not confirmed with rifampicin 
resistance on repeat Xpert testing, Sanger rpoB gene 
sequencing was done on remnants of sputum sample 2, 
using a nested PCR system covering both the rifampicin-
resistance determining region and the non-rifampicin-
resistance determining region, as previously described.15 
If tests on the sputum sample did not produce a result, the 
tests were repeated on the corresponding culture isolate, if 
available. Furthermore, some participants under went 
next-generation sequencing using sample 2 or 3. 
Deeplex-MycTB (Deeplex; GenoScreen, Lille, France) is a 
targeted deep-sequencing assay that was done on sputum 
DNA extracts.16 Moreover, whole-genome sequencing 
(WGS) was done on isolate DNA17 on an Illumina HiSeq 
platform using the Nextera XT DNA Library Preparation 
Kit (Illumina, San Diego, CA, USA). Single nucleotide 
polymorphisms (SNPs) were detected from WGS reads by 
first filtering out non-M tuberculosis DNA using Centrifuge 
version 1.0.318 and then calling SNPs against the 
reconstructed ancestor genome19 using MTBseq.20
We obtained data for Xpert bacillary load for all 
tuberculosis patients with rifampicin resistance on the 
initial Xpert assay and smear positivity for all notified 
tuberculosis cases from routine programmatic records.
Final rifampicin resistance status was ascertained 
using a composite reference standard. If any documented 
rifampicin resistance-conferring mutations were identi-
fied by any sequencing technique, including mutations 
coexisting with wild-type bacilli (hetero resistance; with 
minimum filtering set at 3% minority reads in Deeplex 
and 5% in WGS analysis), the participant was judged to 
have true rifampicin-resistant tuberculosis.21 Total 
absence of a resistance mutation (ie, wild-type) meant 
that the individual was regarded as susceptible to 
rifampicin and, thus, a false rifampicin-resistant result 
on the initial Xpert assay. When no sequencing result 
was available, the pDST result was regarded as the 
reference standard, particularly to confirm rifampicin 
resistance. If no sequencing and pDST results were 
available, rifampicin resistance was deemed unknown.
Statistical analysis
We used Pearson’s χ² test and Fisher’s exact test to 
investigate associations between false rifampicin 
resistance and potential predictors, comprising bacillary 
load on initial Xpert testing (high [Ct<16], medium 
[16≤Ct<22], low [22≤Ct≤28], and very low [Ct>28]), previous 
history of tuberculosis treatment (tuberculosis retreatment 
vs new tuberculosis), HIV co-infection status (HIV-positive 
vs HIV-negative), and specific probe reactions (probe E 
or probe B vs other probes combined, a binary variable 
grouping together probes with a higher frequency of false 
rifampicin resistance). Pearson’s χ² test was used to 
investigate associations between bacillary load on initial 
Xpert testing and HIV co-infection, as well as between the 
year of diagnosis and the proportion of patients with a 
microscopy-positive smear. We judged a p value less than 
0·05 statistically significant. Multi variable Firth logistic 
regression was used to assess predictors of discordance 
between the initial and the repeat Xpert and predictors of 
false rifampicin resistance, adjusted for HIV status, 
tuberculosis treatment history, initial Xpert semi-
quantitative bacillary load, and initial Xpert probe. We 
judged an odds ratio (OR) significant if the 95% CI 
excluded 1·0. We used Stata version 14.2 for data analysis.
The DIAMA trial is registered with ClinicalTrials.gov, 
NCT03303963.














Male 119 39 41 0 39
Female 35 15 5 1 14
Age, years
<30 49 16 12 0 21
30–44 52 24 16 0 12
45–54 28 8 7 1 12
>54 25 6 11 0 8
Tuberculosis treatment history
New 118 41 37 1 39
Retreatment 36 13 9 0 14
HIV status
Positive 56 24 14 0 18
Negative 93 28 30 1 34
Unknown 5 2 2 0 1
Bacillary load of sputum sample*
High (1+ to 3+) 44 38 5 0 1
Low (scanty) 41 12 19 1 9
Negative 69 4 22 0 43
Initial Xpert result, semi-quantitative bacillary load (Ct value)
High (Ct<16) 26 23 1 0 2
Medium 
(16≤Ct<22)
21 19 1 1 0
Low (22≤Ct≤28) 13 8 2 0 3
Very low (Ct>28) 94 4 42 0 48
Initial Xpert result, absent or delayed probe binding
Probe A 10 0 5 0 5
Probe B 19 10 3 0 6
Probe C 6 0 3 0 3
Probe D 19 2 10 0 7
Probe E 90 42 20 1 27
Probe X† 10 0 5 0 5
Data are number of patients. Xpert=classic Xpert MTB/RIF assay. Ct=PCR threshold cycle. *Ascertained by direct 
fluorescence microscopy. †More than one probe. 
Table 1: Characteristics of patients with rifampicin-resistant tuberculosis on initial Xpert testing, 
stratified by findings of repeat Xpert testing
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Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
JCSN, BCdJ, and DA had full access to all data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
From May 4, 2017, to April 30, 2019, 193 individuals in 
Rwanda started MDR-tuberculosis treatment. Among 
this population, 175 (91%) people were identified with 
rifampicin-resistant tuberculosis on initial Xpert testing 
and were eligible for our analysis, of whom 154 (88%) 
had both initial and repeat Xpert results available and 
were included in our analysis (figure 1; table 1). 21 patients 
excluded did not have data available on initial Xpert 
semi-quantitative bacillary load.
Of 154 patients with rifampicin resistance on initial 
Xpert testing, 100 (65%) did not have rifampicin resistance 
on repeat Xpert testing (figure 1; figure 2; table 1). 
46 (30%) patients were deemed susceptible to rifampicin, 
one (1%) had indeterminate rifampicin resistance, and 
53 (34%) were tuberculosis-negative (figure 1; table 1). Of 
54 (35%) patients with rifampicin resistance confirmed 
on repeat Xpert testing, all had the same rifampicin 
resistance-determining probe reaction as on the 
corresponding initial Xpert assay; four (8%) patients had 
a very low bacillary load on the initial Xpert test (figure 1; 
appendix 2 p 5). 
94 (61%) of 154 patients had a very low bacillary load on 
initial Xpert testing (table 2). These patients had a much 
higher probability of having a discordant repeat Xpert 
result (90 of 94 [96%]) compared with those with a high 
Figure 2: Reference standard testing for patients not confirmed as RR on repeat Xpert testing
All confirmatory tests were concordant. RR=rifampicin resistant. Xpert=classic Xpert MTB/RIF assay. RS=rifampicin susceptible. pDST=phenotypic drug 




not confirmed on 
repeat Xpert testing, 
n (%) 
Univariate 




odds ratio (95% CI)* 
HIV status
Negative 93 65 (70%) 1 (ref) 1 (ref)
Positive 56 32 (57%) 0·6 (0·3–1·1) 0·6 (0·2–1·8)
Tuberculosis treatment history
Retreatment 36 23 (64%) 1 (ref) 1 (ref)
New 118 77 (65%) 1·1 (0·5–2·3) 4·7 (0·9–24·3)
Bacillary load of sputum sample†
High (1+ to 3+) 44 6 (14%) 1 (ref) ··
Low (scanty) 41 29 (71%) 15·3 (5·1–45·6) ··
Negative 69 65 (94%) 102·9 (27·3–388·0) ··
Initial Xpert result, semi-quantitative bacillary load (Ct value)
High (Ct<16) 26 3 (12%) 1 (ref) 1 (ref)
Medium 
(16≤Ct<22)
21 2 (10%) 0·8 (0·1–5·3) 1·0 (0·2–5·6)
Low (22≤Ct≤28) 13 5 (38%) 4·8 (0·9–24·8) 4·6 (0·9–22·9)
Very low (Ct>28) 94 90 (96%) 172·5 (36·1–825·4) 118·4 (22·2–631·4)
Initial Xpert result, absent or delayed probe binding
Probe E or B 109 57 (52%) 1 (ref) 1 (ref)
Other probes‡ 45 43 (96%) 19·6 (4·5–85·0) 3·0 (0·5–17·0)
Rifampicin resistance was not confirmed on repeat Xpert testing in 100 patients. Xpert=classic Xpert MTB/RIF assay. 
Ct=PCR threshold cycle. *Adjusted for HIV status, tuberculosis treatment history, initial Xpert semi-quantitative 
bacillary load, and initial Xpert probe. †Ascertained by direct fluorescence microscopy; not included in multivariable 
analysis because measures of bacillary load are not independent. ‡Probes A, C, D, and more than one probe together. 
Table 2: Factors associated with failure to confirm initial rifampicin-resistant Xpert result on repeat 
Xpert testing
 10 confirmed RR
67 reference standard results available
33 excluded (reference standard 
      results not available)
100 not confirmed RR on repeat Xpert testing
 1 pDST, Sanger 
   and WGS
 3 pDST and 
   Sanger
 2 pDST and 
   Deeplex
 1 pDST and WGS 2 Sanger 
  
 1 Deeplex
2 pDST, Sanger, 
   Deeplex, and 
   WGS
 6 pDST, Sanger, 
   and WGS
 10 pDST, Sanger, 
     and Deeplex
 1 pDST and WGS  33 pDST and  
     Sanger
 2 Deeplex and 
   Sanger
3 Sanger
 57 confirmed RS
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bacillary load on initial Xpert testing (three of 26 [11%]; 
adjusted OR 118·4, 95% CI 22·2–631·4; p<0·0001; 
table 2; appendix 2 p 5). HIV co-infection did not affect 
bacillary load on initial Xpert testing, with 30 (54%) of 
56 patients with HIV co-infection and 61 (66%) of 
93 HIV-negative patients having a very low bacillary load 
(p=0·40; appendix 2 p 5). 
121 (79%) of 154 patients had a final known status for 
rifampicin susceptibility (figure 1; appendix 2 pp 1–4). 
Samples from the remaining 33 patients (of whom 
25 were tuberculosis negative and eight were rifampicin 
susceptible on repeat Xpert testing) remained culture-
negative and without a reference test result, despite 
repeated culture attempts. 57 (47%) of 121 patients with a 
final status were identified as false rifampicin resistant on 
initial Xpert testing (not questioning the specificity for 
detection of tuberculosis) whereas 64 (53%) had true 
rifampicin resistance (figure 1).
Of the 57 patients with false rifampicin resistance 
(figure 2), rpoB sequencing showed wild-type DNA for 
54 (95%), and three had mutations outside the rifampicin-
resistance determining region that were not associated 
with rifampicin resistance (Gly386Asp and Thr585Ile). Of 
the 54 patients with a wild-type rpoB sequence, 50 had a 
pDST result available, and all were rifampicin susceptible. 
Of the 57 patients with false rifampicin resistance, 50 were 
new tuberculosis patients and seven needed retreatment 
(five had initial treatment failure and two had relapse; 
adjusted OR 6·0, 95% CI 1·0–35·0; table 3).
Of the 64 patients with true rifampicin resistance on 
initial Xpert testing, 56 had MDR-tuberculosis with 
resistance also to isoniazid, whereas none had tuberculosis 
resistant to fluoroquinolones or second-line injectable 
drugs. Of the 54 patients with concordant rifampicin 
resistance on both initial and repeat Xpert testing, 21 (39%) 
were confirmed as rifampicin resistant by both pDST and 
deep sequencing, 31 (57%) by pDST alone, and two (4%) by 
deep sequencing alone. Among the remaining ten (16%) 
patients who did not have rifampicin resistance on repeat 
Xpert testing, but in whom rifampicin resistance was 
confirmed by reference methods (figure 2), four had 
heteroresistance (three on deep sequencing and one on 
Sanger sequencing) reported as rifampicin susceptible 
(n=3) and tuberculosis negative (n=1) by the repeat Xpert 
assay and six had fixed high-confidence resistance-
conferring mutations in the rpoB gene (five on Sanger 
sequencing and one on WGS). Of these six patients, 
five had a tuberculosis-negative result on repeat Xpert 
testing and one was not interpretable (indeterminate 
rifampicin resistance) by the repeat Xpert assay. Among 
these ten patients who were not rifampicin resistant on 
repeat Xpert, five were detected as rifampicin resistant 
during MDR-tuberculosis treatment by follow-up Xpert 
assay (three tested rifampicin resistant at month 1 and 
another two tested rifampicin resistant at month 2), 
four remained tuberculosis negative, and one patient died 
before the first follow-up Xpert assay was done. Of these 
same ten patients not confirmed rifampicin resistant on 
repeat Xpert assay, nine were new tuberculosis patients 
whereas one had had treatment failure.
Among the 121 patients with a final known status for 
rifampicin susceptibility, the likelihood of false rifampicin 
resistance on initial Xpert assay was highest in patients 
with very low bacillary load (54 of 63 [86%]) compared with 
those with low (two of 13 [15%]), medium (none of 
21 [0%]), or high (one of 24 [4%]) bacillary loads. By 
multivariable analyses, a very low bacillary load (adjusted 
OR 63·6, 95% CI 9·9–410·4) and an absent or delayed 
probe other than B or E on initial Xpert testing 
(8·6, 1·5–49·1) were associated with false rifampicin 
resistance (table 3).
Discussion
The findings of our population-based study in Rwanda 
show that the Xpert assay has a low positive predictive 
value (53%) for rifampicin resistance in sputum samples 
with a very low bacillary load. To be identified many years 
after global roll-out of the Xpert assay, this finding is 
alarming.
The low positive predictive value of the Xpert assay is 
the outcome of imperfect specificity in the context of low 
prevalence of rifampicin resistance and an increase in 
patients with paucibacillary presentation because of 










odds ratio (95% CI)*
HIV status
Negative 71 37 (52%) 1 (ref) 1 (ref)
Positive 46 18 (39%) 0·6 (0·3, 1·3) 0·6 (0·2–2·2)
Tuberculosis treatment history
Retreatment 21 7 (33% 1 (ref) 1 (ref)
New 100 50 (50%) 2 (0·74–5·4) 6·0 (1·0–35·0)
Bacillary load of sputum sample†
High (1+ to 3+) 44 5 (11%) 1 (ref) ..
Low (scanty) 35 18 (51%) 8·3 (2·63–25·9) ..
Negative 42 34 (81%) 33·2 (9·9–111·0) ..
Initial Xpert result, semi-quantitative bacillary load (Ct value)
High (Ct<16) 24 1 (4%) 1 (ref) 1 (ref)
Medium (16≤Ct<22) 21 0 0·4 (0·0–9·4) 0·5 (0·0–12·5)
Low (22≤Ct≤28) 13 2 (15%) 4·2 (0·3–51·2) 3·3 (0·4–30·0)
Very low (Ct>28) 63 54 (86%) 138 (16·5–1153·0) 63·6 (9·9–410·4)
Initial Xpert result, absent or delayed probe binding
Probe E or B 92 30 (33%) 1 (ref) 1 (ref)
Other probes‡ 29 27 (93%) 27·9 (6·2–125·2) 8·6 (1·5–49·1)
121 patients had documented rifampicin results on reference standard, of whom 57 (47%) had false rifampicin 
resistance. Xpert=classic Xpert MTB/RIF assay. Ct=PCR threshold cycle. *Adjusted for HIV status, tuberculosis treatment 
history, initial Xpert semi-quantitative bacillary load, and initial Xpert probe. †Ascertained by direct fluorescence 
microscopy; not included in multivariable analysis because measures of bacillary load are not independent. ‡Probes A, 
C, and D together.
Table 3: Predictors of false rifampicin resistance on initial Xpert assay, in patients with rifampicin results 
ascertained by reference standard
See Online for appendix 2
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tested earlier during tuberculosis disease. Absence of 
probe binding seems to be caused by insufficient 
mycobacterial DNA in the sample, rather than being 
related to absence or delayed binding of a specific probe, 
such as B or E, as previously suggested.4,9 Indeed, our 
findings showed that an absent or delayed probe other 
than B or E was associated with false rifampicin resistance. 
However, probe reactions might reflect distinct mutations, 
which can vary between settings, making the implications 
of this finding difficult to elucidate. Moreover, coexistence 
of multiple mutations, which together affect more than 
one probe, has been reported.22 False rifampicin resistance 
on Xpert testing of paucibacillary sputum samples might 
be attributable to unequal dynamics of target hybridisation 
for different probes, which could have a greater effect after 
extended PCR cycles.4,23
In our setting, false rifampicin resistance was not 
associated with HIV co-infection, probably because the 
frequency of paucibacillary samples was similar among 
patients with HIV co-infection and those who were HIV-
negative. In Rwanda, the diagnostic strategy for 
tuberculosis now favours earlier access to Xpert testing. 
Therefore, patients who are HIV-negative are also 
diagnosed at the paucibacillary stage of disease.
The classic Xpert assay continues to be used in most 
endemic areas and countries, although the novel Xpert 
Ultra assay has started to be deployed since 2017.24 This 
newer assay has shown higher sensitivity to detect 
tuberculosis and greater specificity for prediction of 
rifampicin resistance compared with the classic Xpert 
assay. Moreover, the Xpert Ultra assay is apparently 
unaffected by very low bacillary load, although a 
rifampicin result is withheld in case of scanty results.1,24 
Unlike the classic Xpert assay tested in our study, with 
which resistance is ascertained on the basis of an absent 
signal (risking non-specific causes of error such as 
insufficient DNA), detection of rifampicin resistance with 
the Xpert Ultra assay is based on melting temperature 
shifts caused by rifampicin resistance-conferring 
mutations in the rifampicin-resistance determining 
region.24 Rwanda plans to gradually implement the Xpert 
Ultra assay, beginning in July, 2020. The price of the Ultra 
and classic assays is the same and procedures are similar. 
Staff at peripheral health centres will be trained on 
interpretation of results. A postimplementation field 
study will need to confirm the higher specificity of the 
Xpert Ultra assay versus the classic Xpert test for detection 
of rifampicin resistance, which was previously assessed 
on spiked samples.24
One repeat Xpert assay proved insufficient to rule out 
rifampicin resistance, particularly in patients with 
heteroresistance, for which the classic Xpert assay limit of 
detection requires a minority population of more than 
50% and is only slightly better with the Xpert Ultra assay, 
depending on the rpoB mutation.24 Other retesting 
samples were tuberculosis negative, probably as a result 
of bacillary loads close to the limit of detection of the 
assay. In our setting, if the decision to start MDR-
tuberculosis treatment had relied on one repeat Xpert 
assay, ten (16%) of 64 patients with true rifampicin 
resistance would have been missed. During MDR-
tuberculosis treatment follow-up, half of these patients 
were identified as rifampicin resistant on Xpert after 1 or 
2 months of treatment. Indeed, repeat testing on samples 
with a higher bacillary load (higher than very low) would 
increase the probability of detecting true rifampicin 
resistance.25
The GLI guideline recommends to accept the result of a 
repeat Xpert assay in patients with a low pretest probability 
of rifampicin resistance (eg, in new tuberculosis cases) 
and to consider the initial Xpert result of rifampicin 
resistance as definitive if the patient is at high risk of 
rifampicin resistance (eg, in patients needing retreat-
ment).10,11 However, our findings showed that a high 
pretest probability of rifampicin resistance (ie, in people 
previously treated for tuberculosis) did not lower the 
Figure 3: Proposed and currently implemented algorithm for initial 
rifampicin-resistant tuberculosis Xpert investigation implemented in 
Rwanda
Category 1 anti-tuberculosis regimen consists of 6 months of rifampicin and 
isoniazid, complemented with ethambutol and pyrazindamid during the first 
2 months of treatment. MDR=multidrug resistant. pDST=phenotypic drug 
susceptibility testing. Xpert=classic Xpert MTB/RIF assay. *Repeat Xpert testing 
should be done at the same place as the initial test, to limit delay. †Repeat Xpert 
testing should be done at the treatment centre, to rule out any clerical error that 
might happen at peripheral testing sites.
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likelihood of false rifampicin resistance on Xpert testing, 
driven by a very low tuberculosis bacillary load rather than 
pretest risk. Thus, although the GLI guideline might 
prevent unnecessary MDR-tuberculosis treatment in new 
cases of tuberculosis, it would not prevent unnecessary 
MDR-tuberculosis treatment in many patients needing 
retreatment with false rifampicin resistance on one Xpert 
assay because of a very low bacillary load. The proposed 
algorithm being implemented in Rwanda since Jan 3, 2020 
(figure 3) initiates an investigation of false rifampicin 
resistance in patients with very low or low bacillary load 
on Xpert testing, regardless of treatment history, whereas 
patients with a medium or high bacillary load continue to 
be swiftly transferred for MDR-tuberculosis treatment 
initiation at a specialised MDR-tuberculosis clinic, where 
a confirmatory repeat test will be done to exclude clerical 
error. Considering the prevalence of rifampicin-resistant 
tuberculosis in Rwanda, this modified flowchart could 
lead to approximately 60 repeat samples per year, divided 
over 68 testing facilities, implying a negligible increase of 
cost and workload.
In Rwanda, unpublished data from the National 
Tuberculosis control programme show the proportion of 
patients with a positive smear has fallen from 89% 
(95% CI 88–90) in 2016 to 68% (67–70) in 2017 and 41% 
(39–42) in 2018 (p<0·0001). The proportion of patients 
with a microscopy-negative smear, reflecting low bacillary 
loads, has steadily increased from 11% (95% CI 10–12) in 
2016 to 59% (58–61) in  2018, as has the proportion with a 
very low bacillary load among the rifampicin-resistant 
population on Xpert—from 10% (95% CI 7–14) between 
2012 and 2016 to 61% (53–68) between 2017 and 2019 
(p<0·0001). This trend is probably attributable to the 
policy of using Xpert testing as the initial diagnostic 
method for all patients with presumptive tuberculosis in 
Kigali.26 The number of patients with false rifampicin 
resistance is expected to increase when Xpert is used as 
the initial diagnostic test in all patients with presumptive 
tuberculosis in Rwanda. The Xpert assay is more 
sensitive than is smear microscopy, particularly for 
paucibacillary tuberculosis.27 Moreover, patients are 
investigated at an early stage, typically with paucibacillary 
tuberculosis, because of active case-finding and the 
integration of tuberculosis services in the community 
health package.12 Our findings and their implications in 
terms of a modified testing algorithm probably apply to 
many other settings in which the classic Xpert assay 
continues to be used for early diagnosis and active case-
finding strategies, as per WHO recommendations.28 
Moreover, the higher risk of false rifampicin resistance 
with Xpert testing on samples with a low bacillary load is 
also important for children29 and people with 
extrapulmonary tuberculosis,30 who generally present 
with paucibacillary tuberculosis.
Compared with use of the Xpert assay as an initial 
diagnostic method (eg, in Kigali), the problem of false 
rifampicin resistance has not been seen when Xpert 
testing is used after a positive smear, including in drug-
resistance surveys targeting smear-positive patients who 
are subsequently tested with the Xpert assay.31 Our 
findings indicate that using Xpert for determination of 
rifampicin resistance in tuberculosis prevalence surveys, 
with testing irrespective of clinical symptoms or 
microscopy results, risks resulting in an unacceptably 
high error rate for false rifampicin resistance.
Our analysis had several important strengths. First, we 
used a large population-based sample to investigate the 
frequency of and factors associated with false rifampicin 
resistance results on Xpert assay. Since we used a 
national sample, our findings are representative of the 
general population of Rwanda, and probably of many 
other countries similarly characterised by a high 
tuberculosis notification rate, early tuberculosis 
diagnosis, low prevalence of rifampicin resistance, and 
universal Xpert testing. Second, we used a comprehensive 
set of reference standards, including classic Sanger 
sequencing, deep sequencing, and pDST. Our findings 
informed  a revision of the Xpert testing algorithm in 
Rwanda and might trigger similar evaluations in other 
countries.
Our study also has some limitations. First, despite 
training, close supervision, and a quality improvement 
scheme initiated at all peripheral centres doing Xpert 
testing, the handling of samples at these sites might differ 
from how samples are obtained at the central MDR-
tuberculosis clinic and tested at the NRL. However, our 
findings still represent how Xpert is used by the Rwandan 
tuberculosis programme. Second, the final rifampicin 
resistance status was not available for 54 (31%) of 
175 patients (21 patients did not have data for the initial 
Xpert semi-quantitative bacillary load and 33 did not have 
a reference standard result). 40 (74%) of 54 patients had a 
very low bacillary load (appendix 2 p 5). As a result, we 
might have underestimated the proportion with false 
rifampicin resistance. Moreover, not all patients had 
results for all the different tests used in this investigation 
(figure 2)—in particular, deep sequencing for hetero-
resistance, because of challenges related to studying 
paucibacillary tuberculosis. However, only one of four 
results found heteroresistance on deep sequencing that 
had been missed by the other tests. Finally, our study did 
not consider chronic comorbidities other than HIV. 
Moreover, data for CD4 cell counts, antiretroviral therapy, 
and viral load were not available.
In summary, a very low tuberculosis bacillary load in 
sputum is the main driver of false rifampicin resistance 
results in the Xpert assay, leading to an unacceptably low 
positive predictive value in settings with a low prevalence 
of rifampicin resistance. For as long as the classic Xpert 
assay is used in Rwanda, we will assess the effect of 
a modified Xpert testing algorithm. Among patients 
with pauci bacillary tuberculosis, those with at least 
one repeat confirmed rifampicin resistance test will be 
treated with an MDR-tuberculosis regimen. However, 
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patients with no repeat Xpert test yielding rifampicin 
resistance at the time of diagnosis will be treated with 
first-line anti-tuberculosis treatment and monitored 
closely, including baseline culture, pDST, and Xpert 
testing during treatment. If the higher specificity of the 
Xpert Ultra assay is confirmed in field settings, and on 
specimens with a very low bacillary load, countries 
should plan to implement Xpert Ultra as soon as 
possible to overcome limitations associated with the 
classic Xpert assay, while it would be prudent to continue 
monitoring false rifampicin resistance in paucibacillary 
samples.
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